Academic journal

Immunicum publishes the mechanism of action of DCP-001 in the

Press release

Stockholm, Sweden, November 22, 2021

Immunicum publishes DCP-001 mechanism of action in Journal Cells

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on hard-to-treat established tumors and prevention of cancer recurrence, today announced the publication of an article in a scientific journal describing the mechanism of action of her relapsed cancer cell-based DCP-001 vaccine. Publication in the peer-reviewed journal Cells details the interaction between DCP-001 and antigen presenting cells and the cellular pathways involved. The study supports a mechanism of action by which the transfer of antigenic material, including antigens associated with tumors, and the activation of the patient’s own antigen-presenting cells upon injection of DCP-001 into the skin leads to the induction of immune responses against tumor cells. The proposed mechanism of action supports the development of DCP-001 as an allogeneic, ready-to-use product that activates the patient’s immune system, with an excellent safety profile and relative ease of administration by intradermal injection. , not requiring lymphodepletion or other preconditioning. Immunicum conducted the study in collaboration with leading immunology researchers at Amsterdam University Medical Center (AUMC) and Northeastern University in Boston.

“This publication provides a detailed overview of the mode of action of DCP-001 and identifies pathways that could serve as a basis for developing potential new combination therapies such as blockade of the CD47-SIRPα immune checkpoint pathway”,
said Alex Karlsson-Parra, MD, Ph.D., Scientific Director of Immunicum. “The publication also strengthens our scientific leadership in the field of allogeneic dendritic cell biology. We are grateful for the collaboration with our academic partners and will continue to leverage our combined expertise to create a pipeline of promising, ready-to-use cellular immunotherapies.

Data published in Cells show that DCP-001 exchanges its cellular content with antigen presenting cells via a phagocytosis process, in which phosphatidylserine plays an important role and which is further enhanced by blocking CD47. The study included a ex vivo model for intradermal injection using human skin tissue samples. Following intradermal injection, DCP-001 initiates the activation of alloreactive T cells residing in the skin, causing local inflammation and attraction of the host’s dendritic cells (DCs). DCP-001 is digested by attracted DCs, resulting in transfer of tumor associated antigens, which in turn leads to the migration of the patient’s own DCs to the draining lymph nodes to initiate the process of priming of the tumor. tumor specific T cells. The described mechanism of action supports the promising characteristics of DCP-001 as a cancer relapse vaccine providing active immunization and a long-lasting anti-tumor immune response aimed at reducing tumor recurrence.

“The study demonstrating the activation of the patient’s own antigen presenting cells by DCP-001 is consistent with observations from our clinical trials to date. We continue to see the potential of DCP-001 to induce immune responses to a wide range of tumor-associated antigens in the Phase II ADVANCE II clinical study in patients with acute myeloid leukemia ”,
commented Jeroen Rovers, MD, Ph.D., Medical Director of Immunicum. “We look forward to presenting the clinical follow-up data that will now cover the full ADVANCE II study cohort for the first time at the American Society of Hematology (ASH) annual meeting next month. “

The full publication titled “Transfer of Cellular Content from the Allogeneic Cell-Based Cancer Vaccine DCP-001 to Host Dendritic Cells Hinges on Phosphatidylserine and Is Enhanced by CD47 Blockade” is available through the current online version of Cells in the special issue of Allogeneic Cell Cancer Immunotherapies.

About DCP-001
Immunicum’s DCP-001 clinical program is generated by transforming a proprietary leukemia cell, DCOne®, into a cell-based cancer vaccine, thereby conserving endogenous tumor antigens while having the profile of a mature dendritic cell. While the leukemia cells used as the starting material were weakly immunogenic, DCP-001 has been shown to be highly immunogenic due to its mature allogeneic dendritic cell phenotype, making it an attractive cancer vaccine candidate. Due to its unique hybrid properties, DCP-001 is able to induce active immunization which leads to long-lasting and specific anti-tumor responses. Immunicum received the EMA’s advanced therapy drug classification for DCP-001 in June 2021.


Erik Manting
Chief Executive Officer
E-mail: [email protected]


Brendan Payne
Serious investor relations
Telephone: +1 212-698-8695
E-mail: [email protected]

For Sweden:

Kristina Windrup Olander
Spikinc AB
Telephone: +46 8 732 8400
E-mail: [email protected]


Eva Mulder and Sophia Hergenhan
Communication Trophy
Telephone: +49 89 2388 7731
E-mail: [email protected]

About Immunicum AB (published)

Immunicum is a biopharmaceutical company focused on hard-to-treat, established tumors and prevention of cancer recurrence, two key challenges in oncology. We are leveraging our unrivaled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, ready-to-use cell therapies for solid and hematogenous tumors. Based in Sweden and the Netherlands, Immunicum is listed on Nasdaq Stockholm.

  • 20211122_Immunicum_Cells Publication_ENG_final